![Ruo Yu Chen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ruo Yu Chen
Geen lopende functies
Vermogen: - $ op 31-05-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Ying Luo | M | 57 |
GNI USA, Inc.
![]() GNI USA, Inc. BiotechnologyHealth Technology GNI USA, Inc. engages in therapeutic pharmaceutical products development and production. The company was founded in 2001 and is headquartered in San Jose, CA.
GNI-EPS Pharmaceuticals, inc.
Cullgen Shanghai, Inc.
Cullgen, Inc.
![]() Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA.
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China.
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | 14 jaar |
Weiguo Ye | M | 47 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China.
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | 8 jaar |
Song Jiang Ma | M | 68 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China.
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | 22 jaar |
Thomas Eastling | M | 63 |
GNI USA, Inc.
![]() GNI USA, Inc. BiotechnologyHealth Technology GNI USA, Inc. engages in therapeutic pharmaceutical products development and production. The company was founded in 2001 and is headquartered in San Jose, CA.
Cullgen, Inc.
![]() Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA.
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 9 jaar |
Bing Chen | M | 40 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China.
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | 5 jaar |
Jianyuan Luo | M | 61 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China.
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | 5 jaar |
Han Ying | M | 59 | 1 jaar | |
Charles Wu | M | 64 |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | 4 jaar |
Hiroyuki Sato | M | 70 |
GNI-EPS Pharmaceuticals, inc.
| 9 jaar |
Hui Xia | M | 44 |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | - |
Nassim Usman | M | 64 | 1 jaar | |
Jie Chen | F | 50 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 5 jaar |
Guowei Zhu | M | 50 |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | - |
Jian Jin | M | - |
Cullgen, Inc.
![]() Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | - |
Gordon Carmichael | M | 75 | 1 jaar | |
Renate Parry | M | 61 | 1 jaar | |
Cui Ping Gu | M | 44 |
Cullgen, Inc.
![]() Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | - |
Xiaogang Pan | M | - |
Cullgen, Inc.
![]() Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | - |
Rodney Nussbaum | M | 68 |
Cullgen, Inc.
![]() Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | 6 jaar |
Zeng Zhang | M | - |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | - |
Jing Wang | M | - |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | - |
Xing Yuan Cheng | M | - |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | - |
Yuwen Wu | F | 56 |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | - |
Gerald Yakatan | M | 82 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 5 jaar |
Youming Cheng | M | 69 |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | - |
S. Yan | M | - |
Cullgen, Inc.
![]() Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | 3 jaar |
Qijia Liu | M | 43 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 7 jaar |
Yanping Ye | M | 41 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 6 jaar |
Ling Zhang | M | 52 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 6 jaar |
Zhenhui Chu | M | - |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 12 jaar |
Mingli Zhu | M | 51 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 15 jaar |
Lin Han | M | 52 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 6 jaar |
Xiao Xing Jiang | M | 42 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 7 jaar |
Yue Xiong | M | - |
Cullgen, Inc.
![]() Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | - |
Hitoshi Matsuda | M | 71 |
GNI-EPS Pharmaceuticals, inc.
| 11 jaar |
Po Man Mak | F | 40 |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | - |
Qingmei Zhu | F | - |
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | 12 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Wei Ming Yi | M | 60 |
Nankai University
| 9 jaar |
Yingshun Chen | M | 58 |
Nankai University
| 16 jaar |
Xian Liang Xiong | M | 56 |
Nankai University
| 4 jaar |
Toru Saito | M | 66 | - | |
Qiang Liu | M | 55 |
Nankai University
| 4 jaar |
Zi Li he | M | 67 |
Nankai University
| 9 jaar |
Jin Ping Dai | M | 59 |
Nankai University
| 5 jaar |
Yun Xia Zhang | F | 59 |
Nankai University
| 6 jaar |
Yu Hua Zhao | M | 56 |
Nankai University
| 6 jaar |
Jun Min Liu | M | 74 |
Nankai University
| 5 jaar |
Tao Zhang | M | 53 |
Nankai University
| 4 jaar |
Xiang Yang Lu | M | 60 |
Nankai University
| 1 jaar |
Yu Long Zhu | M | 53 |
Nankai University
| 4 jaar |
Lei Sun | M | 52 |
Nankai University
| 4 jaar |
Li Ren | M | 57 |
Nankai University
| 4 jaar |
Zhong Fu Ma | M | 56 |
Nankai University
| 4 jaar |
Zheng Zhang | M | 52 |
Nankai University
| 4 jaar |
Dongqi Chen | M | 55 |
Nankai University
| 4 jaar |
Xiang Gao | M | 52 |
Nankai University
| 4 jaar |
Xing Huang | M | 50 |
Nankai University
| 4 jaar |
Simon Dazhong Lu | M | 55 |
Nankai University
| 4 jaar |
Jun Min Liu | M | 74 |
Nankai University
| 3 jaar |
Xiao Bing Li | M | 56 |
Nankai University
| 5 jaar |
Ze Min Zhang | M | 57 |
Nankai University
| 4 jaar |
Baoning Shi | M | 52 |
Nankai University
| 4 jaar |
Hong Jun Mi | M | 53 |
Nankai University
| 4 jaar |
Chuan Xin Zhao | M | 59 |
Nankai University
| 4 jaar |
Hong Peng Wang | M | 50 |
Nankai University
| 4 jaar |
Ji LI Xu | F | 53 |
Nankai University
| 4 jaar |
Hong Song | F | 56 |
Nankai University
| 4 jaar |
Azhong Ye | M | 61 |
Nankai University
| 1 jaar |
Ze Yu | M | 52 |
Nankai University
| 4 jaar |
Jian Dong Wang | M | 61 |
Nankai University
| 3 jaar |
Yu Ge Jia | M | 55 |
Nankai University
| 8 jaar |
Su Hui Qu | F | 58 |
Nankai University
| 3 jaar |
Chuan Ming Chen | M | 67 |
Nankai University
| 3 jaar |
Yi Qun Xie | M | 63 |
Nankai University
| 4 jaar |
Yan Jin | M | - |
Nankai University
| 5 jaar |
Wei Lu | F | 58 |
Nankai University
| 4 jaar |
Lijun Shi | M | - |
Nankai University
| 4 jaar |
Yan Wang | M | - |
Nankai University
| 4 jaar |
Sun Quan | M | 57 |
Nankai University
| 4 jaar |
Xiao Mei Liu | F | 54 |
Nankai University
| 4 jaar |
Run Tong Liu | M | 50 |
Nankai University
| 4 jaar |
Zheng Ping Fu | M | 59 |
Nankai University
| 4 jaar |
Guang Bei Xie | M | 70 |
Nankai University
| 1 jaar |
Tong Guan | M | 56 |
Nankai University
| 4 jaar |
Rui Jie Li | M | 57 |
Nankai University
| 4 jaar |
Chang Sheng Duan | M | 52 |
Nankai University
| 4 jaar |
De Gang Lin | M | 51 |
Nankai University
| 5 jaar |
Dong Hao Yang | M | 52 |
Nankai University
| 4 jaar |
Xing Qiang Zhang | M | 58 |
Nankai University
| 4 jaar |
Yong Gang Cao | M | 52 |
Nankai University
| 4 jaar |
Yi Mou | M | 57 |
Nankai University
| 4 jaar |
Hui Zhong Kou | M | 56 |
Nankai University
| 4 jaar |
Jian Ping Tang | M | 60 |
Nankai University
| 4 jaar |
Hua Min Li | F | 50 |
Nankai University
| 4 jaar |
Xiao Bing Ren | M | 57 |
Nankai University
| 4 jaar |
Jing Ru Chen | F | 59 |
Nankai University
| 3 jaar |
Jie Ma | M | 52 |
Nankai University
| 4 jaar |
Nong Yang | M | 55 |
Nankai University
| 4 jaar |
Wei Liu | F | 56 |
Nankai University
| 4 jaar |
Junying Peng | F | 50 |
Nankai University
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
China | 89 | 89.00% |
Verenigde Staten | 8 | 8.00% |
Japan | 2 | 2.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Ruo Yu Chen
- Persoonlijk netwerk